Intellia Therapeutics Inc (0JBU)

Currency in USD
12.33
+0.43(+3.61%)
Closed·
0JBU Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
0JBU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.0012.52
52 wk Range
5.9527.39
Key Statistics
Prev. Close
24.75
Open
12.33
Day's Range
12-12.52
52 wk Range
5.95-27.39
Volume
23.95K
Average Vol. (3m)
33.5K
1-Year Change
-51.93%
Book Value / Share
7.53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0JBU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Intellia Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Compare 0JBU to Peers and Sector

Metrics to compare
0JBU
Peers
Sector
Relationship
P/E Ratio
−2.4x−1.8x−0.5x
PEG Ratio
−0.91−0.110.00
Price / Book
1.6x2.1x2.6x
Price / LTM Sales
27.4x8.2x3.2x
Upside (Analyst Target)
-344.2%44.6%
Fair Value Upside
Unlock18.8%6.5%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-1.10 / -1.27
Revenue / Forecast
16.63M / 12.79M
EPS Revisions
Last 90 days

0JBU Income Statement

People Also Watch

123.02
CRWV
-6.95%
20.75
BEAM
+1.47%
223.78
CRCL
-4.81%

FAQ

What Is the Intellia Therapeutics Inc (0JBU) Stock Price Today?

The Intellia Therapeutics Inc stock price today is 12.33

What Stock Exchange Does Intellia Therapeutics Inc Trade On?

Intellia Therapeutics Inc is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Intellia Therapeutics Inc?

The stock symbol for Intellia Therapeutics Inc is "0JBU."

What Is the Intellia Therapeutics Inc Market Cap?

As of today, Intellia Therapeutics Inc market cap is 1.25B.

What Is Intellia Therapeutics Inc's Earnings Per Share (TTM)?

The Intellia Therapeutics Inc EPS (TTM) is -5.21.

When Is the Next Intellia Therapeutics Inc Earnings Date?

Intellia Therapeutics Inc will release its next earnings report on Nov 06, 2025.

From a Technical Analysis Perspective, Is 0JBU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Intellia Therapeutics Inc Stock Split?

Intellia Therapeutics Inc has split 0 times.

How Many Employees Does Intellia Therapeutics Inc Have?

Intellia Therapeutics Inc has 403 employees.

What is the current trading status of Intellia Therapeutics Inc (0JBU)?

As of Jul 19, 2025, Intellia Therapeutics Inc (0JBU) is trading at a price of 12.33, with a previous close of 24.75. The stock has fluctuated within a day range of 12.00 to 12.52, while its 52-week range spans from 5.95 to 27.39.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.